Compare Nippon India Pharma Fund vs HDFC Pharma And Healthcare Fund
Nippon India Pharma Fund
EquitySectoral-Pharma
HDFC Pharma And Healthcare Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.83
2.12
NAV
₹632.53
₹22.25
Fund Started
10 May 2004
14 Sep 2023
Fund Size
₹9166.40 Cr
₹3501.37 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1%, if redeemed within 30 days.
1 Year
8.21%
22.21%
3 Year
17.42%
29.05%
5 Year
13.29%
-
Equity
97.31%
96.77%
Cash
2.67%
3.23%
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Divi's Laboratories Ltd. | 7.10% |
Lupin Ltd. | 6.17% |
Cipla Ltd. | 6.01% |
Dr. Reddy's Laboratories Ltd. | 5.45% |
Apollo Hospitals Enterprise Ltd. | 4.89% |
Mankind Pharma Ltd. | 4.38% |
Sai Life Sciences Ltd. | 3.92% |
Ajanta Pharma Ltd. | 3.61% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.11% |
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 9.39% |
Sun Pharmaceutical Industries Ltd. | 8.28% |
Alkem Laboratories Ltd. | 4.64% |
Cipla Ltd. | 4.15% |
Apollo Hospitals Enterprise Ltd. | 3.69% |
Torrent Pharmaceuticals Ltd. | 3.65% |
Max Healthcare Institute Ltd. | 3.61% |
Aster DM Quality Care Ltd. | 3.56% |
Lupin Ltd. | 3.55% |
Neuland Laboratories Ltd. | 3.24% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Launch Date
10 May 2004
14 Sep 2023
